
Even though drugs like Ozempic and Rybelsus often steal the attention at Novo Nordisk, the firm is also highly occupied with its insulin business.
Most recently, Novo Nordisk launched the first trial in a large phase III program for the firm's new insulin icodec.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app